コーパス検索結果 (１語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 ss the effect of defined allelic variants on mammary tumorigenesis.
2 cesses may contribute to NF-kappaB-dependent mammary tumorigenesis.
3 MEC NF-kappaB contributes to mammary tumorigenesis.
4 a model system to study the role for Pak4 in mammary tumorigenesis.
5 of STAT3 in myeloid cells leads to enhanced mammary tumorigenesis.
6 lation of Jak2 protects against the onset of mammary tumorigenesis.
7 essor of oncogenic TGF-beta signaling during mammary tumorigenesis.
8 ted a significant suppression in spontaneous mammary tumorigenesis.
9 the oncogenic activities of TGF-beta during mammary tumorigenesis.
10 geted anticancer therapy in a mouse model of mammary tumorigenesis.
11 n of downstream effectors and ErbB2-mediated mammary tumorigenesis.
12 egulated during the process of CR-1-mediated mammary tumorigenesis.
13 K activation and P50 phosphorylation causing mammary tumorigenesis.
14 ptibility gene 1 (BRCA1) plays a key role in mammary tumorigenesis.
15 at tissue overexpression of IGF-1 stimulates mammary tumorigenesis.
16 2/neu transgenes, Hoxb7 plays a dual role in mammary tumorigenesis.
17 ssively restricted to the vasculature during mammary tumorigenesis.
18 of mammary alveolar/lobular development and mammary tumorigenesis.
19 eventing the superantigen (Sag) response and mammary tumorigenesis.
20 nergized with defective apoptosis to promote mammary tumorigenesis.
21 study stromal TGF-beta and HGF signaling in mammary tumorigenesis.
22 ates a requirement for Akt1 in ErbB2-induced mammary tumorigenesis.
23 at cyclin D1 was required for ErbB-2-induced mammary tumorigenesis.
24 markedly with oncogenic ras or neu in murine mammary tumorigenesis.
25 erates with the neu-ras oncogenic pathway in mammary tumorigenesis.
26 cancer tissue and in a mouse model of ErbB2 mammary tumorigenesis.
27 cur early in the process of estrogen-induced mammary tumorigenesis.
28 e antagonist mifepristone (RU 486) prevented mammary tumorigenesis.
29 d in the protection against estrogen-induced mammary tumorigenesis.
30 (Neu DeLetion mutant) model of ErbB2-induced mammary tumorigenesis.
31 for the active role of MMPs in Wnt1-induced mammary tumorigenesis.
32 ts exhibit parity-induced protection against mammary tumorigenesis.
33 on and contributes to the hormonal impact on mammary tumorigenesis.
34 ffect against mammary hyperplasia as well as mammary tumorigenesis.
35 ed, indicating that MET and MYC cooperate in mammary tumorigenesis.
36 of mammary alveolar/lobular development and mammary tumorigenesis.
37 nd indispensable role in MMTV-PyV MT-induced mammary tumorigenesis.
38 ed nonreceptor tyrosine kinase implicated in mammary tumorigenesis.
39 e that Cox-2 contributes to HER2/neu-induced mammary tumorigenesis.
40 e during early events of ErbB2/Neu-initiated mammary tumorigenesis.
41 ways may be a significant determinant during mammary tumorigenesis.
42 eficient mouse model substantially curtailed mammary tumorigenesis.
43 aling and thus stimulates hormone-responsive mammary tumorigenesis.
44 epair machinery as important contributors to mammary tumorigenesis.
45 reast cancers, is capable of contributing to mammary tumorigenesis.
46 ntiation, an effect that could contribute to mammary tumorigenesis.
47 sity at the Ink4a/Arf locus in ErbB2-induced mammary tumorigenesis.
48 t that progesterone has an important role in mammary tumorigenesis.
49 y early mutational target in c-erbB2-induced mammary tumorigenesis.
50 for Brca1 or Brca2 is highly susceptible to mammary tumorigenesis.
51 ent DCIS and, thus, may be an early event in mammary tumorigenesis.
52 ling through PGE2 receptors is important for mammary tumorigenesis.
53 f both Apc and Tcf-1 have been implicated in mammary tumorigenesis.
54 curring in most traditional models of murine mammary tumorigenesis.
55 us insertion results in pregnancy-responsive mammary tumorigenesis.
56 are important in modulating Neu function in mammary tumorigenesis.
57 mber of oncogenes, that ultimately result in mammary tumorigenesis.
58 in cell adhesion may be very early events in mammary tumorigenesis.
59 BRCA2 is a tumor suppressor gene involved in mammary tumorigenesis.
60 iated with and is capable of contributing to mammary tumorigenesis.
61 rstanding of the molecular mechanisms of rat mammary tumorigenesis.
62 eractions of biochemical pathways leading to mammary tumorigenesis.
63 studies that progesterone markedly enhances mammary tumorigenesis.
64 impact the progression of TGFalpha-mandated mammary tumorigenesis.
65 Sv, suggests a genetic predisposition toward mammary tumorigenesis.
66 sis for the role of p53 in the regulation of mammary tumorigenesis.
67 (Fgf8) as a possible proto-oncogene in mouse mammary tumorigenesis.
68 contributing to the fat-induced promotion of mammary tumorigenesis.
69 ted in a 50% reduction of chemically induced mammary tumorigenesis.
70 o determine the effect of MAT on neu-induced mammary tumorigenesis.
71 (OGG1) in the PyMT transgenic mouse model of mammary tumorigenesis.
72 ine the specific effects of this mutation on mammary tumorigenesis.
73 ammary epithelium contributes to early-stage mammary tumorigenesis.
74 eful in the investigation of early events in mammary tumorigenesis.
75 C3(1) 5'-flanking region display multistage mammary tumorigenesis.
76 nstitutively free to function in its role in mammary tumorigenesis.
77 markably protected Brca1-mutant mice against mammary tumorigenesis.
78 ay and promotes nitroso-N-methylurea-induced mammary tumorigenesis.
79 n (PyV MT)-driven mouse model of spontaneous mammary tumorigenesis.
80 umor suppressor role of E2F2 in Myc-mediated mammary tumorigenesis.
81 ammation in the mammary fat pad and promoted mammary tumorigenesis.
82 ole for SIRT5 in metabolic reprogramming and mammary tumorigenesis.
83 ng the CDK-cyclin D1-PELP1 axis in promoting mammary tumorigenesis.
84 ive oxygen species (ROS) on the induction of mammary tumorigenesis.
85 lpha) activity is required for ErbB2-induced mammary tumorigenesis.
86 he pathophysiologic significance of FABP5 in mammary tumorigenesis.
87 ortunity to study the importance of c-Src in mammary tumorigenesis.
88 opment and that it has a suppressive role in mammary tumorigenesis.
89 d in the protection against estrogen-induced mammary tumorigenesis.
90 errant mammary gland development and induces mammary tumorigenesis.
91 t DDE exposure would promote, but not cause, mammary tumorigenesis.
92 f mammary epithelial cells and also promotes mammary tumorigenesis.
93 r probing the cellular signaling pathways in mammary tumorigenesis.
94 r activation and is an important mediator of mammary tumorigenesis.
95 s a key role in both hereditary and sporadic mammary tumorigenesis.
96 d glioma development, but strikingly, delays mammary tumorigenesis.
97 with the Wnt/beta-catenin pathway to promote mammary tumorigenesis.
98 ice, iFGFR1 activation dramatically enhanced mammary tumorigenesis.
99 1 phosphatase in the DNA damage response and mammary tumorigenesis.
100 ine a direct contribution of this pathway in mammary tumorigenesis.
101 timulated by SnoN was insufficient to induce mammary tumorigenesis.
102 of the main estrogen metabolites that induce mammary tumorigenesis and (ii) ROS-mediated signaling le
103 ved in IFN-gamma gene down-regulation during mammary tumorigenesis and contributes to the generalized
105 LILRB4 as a link between CRD and aggressive mammary tumorigenesis and establish the potential role o
106 ssion of d16HER2 is sufficient to accelerate mammary tumorigenesis and improve the response to trastu
107 C3H mouse mammary tumor virus (MMTV)-induced mammary tumorigenesis and lack major histocompatibility
108 Here, we examined the role of caveolin-1 in mammary tumorigenesis and lung metastasis using a molecu
110 s responsible in part for the suppression of mammary tumorigenesis and metastasis caused by inhibitio
111 ta.neu transgenic mice exhibited accelerated mammary tumorigenesis and metastasis compared with MMTV-
112 tor beta (TGF-beta) signaling on Neu-induced mammary tumorigenesis and metastasis was examined with t
113 t2 deletion does not inhibit and exacerbates mammary tumorigenesis and metastasis, but cell-autonomou
121 histone chaperone FACT is upregulated during mammary tumorigenesis and necessary for the viability an
122 xpression of 14-3-3zeta has a causal role in mammary tumorigenesis and progression, acting through mi
123 ongly synergizes with both c-MYC and Wnt1 in mammary tumorigenesis and promotes the progression of tu
124 Loss of miR-10b delays oncogene-induced mammary tumorigenesis and suppresses epithelial-mesenchy
125 genetic silencing of EcSOD may contribute to mammary tumorigenesis and that restoring the extracellul
126 ammary gland morphology and aggressive basal mammary tumorigenesis and the molecular mechanism underl
128 of E2F1 and E2F3 in ErbB2- or Myc-triggered mammary tumorigenesis, and a tumor suppressor role of E2
130 ect role of PPARdelta in the pathogenesis of mammary tumorigenesis, and suggest a rationale for thera
131 we found that ERalpha and ERbeta expression, mammary tumorigenesis, and survival are energy balance d
132 f one copy of APC promotes oncogene-mediated mammary tumorigenesis, Apc(Min/+) mice were crossed with
133 equirement for Cdk2 in LMW-cyclin E-mediated mammary tumorigenesis, arguing that human breast tumors
134 an breast cancers and has been implicated in mammary tumorigenesis as well as in mediating aggressive
135 oinsufficient tumor suppressor mechanism for mammary tumorigenesis, as the essential autophagy regula
136 zed SCRIB functions as a neomorph to promote mammary tumorigenesis by affecting subcellular localizat
137 alleles in the ErbB2 BC model mice abrogates mammary tumorigenesis by blocking the expression of the
138 cooperativity between neu and mutant p53 in mammary tumorigenesis by creating bitransgenic mice carr
140 onstrated that MTDH plays a critical role in mammary tumorigenesis by regulating oncogene-induced exp
142 Although loss of Lkb1 alone does not promote mammary tumorigenesis, combination of Lkb1 deficiency wi
143 nic models, whereas loss of E2f2 accelerated mammary tumorigenesis driven by Myc-overexpression.
144 Mtv-null mice restrict MMTV replication and mammary tumorigenesis even after a robust Sag response.
145 protection against methylnitrosourea-induced mammary tumorigenesis following treatment with pregnancy
146 In this study, we generated a mouse model of mammary tumorigenesis harboring the MMTV-HER2 oncogene a
148 f p62 in the pathophysiology of HER2-induced mammary tumorigenesis has not yet been investigated.
149 esterone receptor (PR) and progestins affect mammary tumorigenesis; however, the relative contributio
150 mice to ascertain the role of Id1 and Id3 in mammary tumorigenesis in a more physiologically relevant
151 mammary epithelium significantly suppresses mammary tumorigenesis in a well-characterized breast can
152 , and treating with anti-progesterone delays mammary tumorigenesis in Brca1/p53 conditional knock-out
154 g individual E2fs in mice on ErbB2-triggered mammary tumorigenesis in comparison to a comparable Myc-
155 deletion of Vhl was not sufficient to induce mammary tumorigenesis in dams bred continuously for up t
156 PTEN can partially inhibit the Wnt-1-induced mammary tumorigenesis in early neoplastic stages by bloc
157 k protein 70 (Hsp72) have been implicated in mammary tumorigenesis in histological investigations of
158 re dynamics and telomerase activation during mammary tumorigenesis in mice carrying a mouse mammary t
160 We have previously shown that c-MYC-induced mammary tumorigenesis in mice proceeds via a preferred s
161 rogen strongly enhanced Pik3caH1047R-induced mammary tumorigenesis in mice that resulted exclusively
162 ncer risk, and inactivation of chk2 enhances mammary tumorigenesis in mice with targeted inactivation
163 AP-p53(172H)) could accelerate ErbB2-induced mammary tumorigenesis in mice, but was not tumorigenic o
168 mechanisms regulated by TFAP2C, we examined mammary tumorigenesis in MMTV-Neu transgenic female mice
170 Diet-stimulated ductal growth also increased mammary tumorigenesis in ovariectomized polyomavirus mid
172 d the ability of tamoxifen to block or delay mammary tumorigenesis in several versions of this model.
173 am), inhibit estrogen-induced DNA damage and mammary tumorigenesis in the aromatase transgenic (Arom)
176 target of rapamycin inhibitor, rapamycin, on mammary tumorigenesis in transgenic mice bearing an acti
179 genetic ablation of p62 delays HER2-induced mammary tumorigenesis in tumor cell allografts in nude m
180 nd cellular mechanisms by which FAK promotes mammary tumorigenesis in vivo are not well understood.
181 l NF-kappaB activity enhances ErbB2-mediated mammary tumorigenesis in vivo by promoting both growth a
183 ow TET2 regulates mammary stem cell fate and mammary tumorigenesis in vivo remains to be determined.
194 ly we have used MMTV infection to accelerate mammary tumorigenesis in Wnt1 transgenic mice in order t
195 suggest that activation of PDK1 can lead to mammary tumorigenesis, in part through PKCalpha, and tha
196 rus middle T oncogene-induced (PyMT-induced) mammary tumorigenesis, increased survival, and reduction
197 nfer a lasting protection against subsequent mammary tumorigenesis induced by methylnitrosourea.
198 mice show substantially prolonged latency in mammary tumorigenesis induced by MMTV-H-ras or MMTV-neu
199 t Hunk is required for c-myc suppression and mammary tumorigenesis induced by phosphatase and tensin
200 t cooperation of the FGF and Wnt pathways in mammary tumorigenesis is based on the activation of prot
203 e show that increased Cdc7 expression during mammary tumorigenesis is linked to Her2-overexpressing a
204 ve and cooperative role for c-Myc and Ras in mammary tumorigenesis is well documented, their ability
205 show that hormone-induced protection against mammary tumorigenesis is widely conserved among divergen
206 nce that KLF4 has a potent oncogenic role in mammary tumorigenesis likely by maintaining stem cell-li
208 role of matrix metalloproteinase 7 (MMP7) in mammary tumorigenesis, MMP7 was expressed in the normal
210 s cancer chemopreventive effects in skin and mammary tumorigenesis models and that additional studies
211 terozygous for p53 synergistically increases mammary tumorigenesis more than that in mice carrying ei
212 ow women's therapies influence all stages of mammary tumorigenesis, particularly for assessing their
213 ys tumor initiation in a transgenic model of mammary tumorigenesis prior to the onset of obesity.
214 hese findings demonstrate that c-MYC-induced mammary tumorigenesis proceeds through a preferred secon
215 ntrast, we now demonstrate that Wnt1-induced mammary tumorigenesis proceeds via a pathway that prefer
216 lity of cyclin E to play a causative role in mammary tumorigenesis, regulatory sequences from the ovi
224 sm underlying the protein's possible role in mammary tumorigenesis, Sca-1 expression was examined in
225 er, we conclude that STAT5 activation during mammary tumorigenesis specifies a tumor phenotype of lac
227 the promotional role of ovarian hormones on mammary tumorigenesis, suggesting that AIB1 and ovarian
228 tively, our data reveal that IQGAP1 enhances mammary tumorigenesis, suggesting that it may be a targe
229 k2 protects against the onset of PRL-induced mammary tumorigenesis, suggesting that targeting this ki
230 NE knockout in the C3(1)TAg mouse model of mammary tumorigenesis suppressed proliferation and reduc
232 cell renewal, luminal cell differentiation, mammary tumorigenesis, tamoxifen sensitivity and chemoth
233 te that, in the setting of viral oncoprotein mammary tumorigenesis, telomerase-dependent telomere mai
235 sts produce diverse, yet profound effects on mammary tumorigenesis that give rise to distinctive hist
236 perates with oncogenic PI3K to promote rapid mammary tumorigenesis, the additional loss of PTEN prote
238 double-strand break sensor MRE11 suppresses mammary tumorigenesis through a pivotal role in regulati
240 vidence that p62 contributes to HER2-induced mammary tumorigenesis through multiple signaling pathway
241 R2/Neu and ACTR may synergize to orchestrate mammary tumorigenesis through the dysregulation of the t
242 The precise sequence of events that enable mammary tumorigenesis to convert transforming growth fac
243 ugh AIB1 deficiency significantly suppressed mammary tumorigenesis under all of the concentrations of
244 done to define the role of fetuin-A (Fet) in mammary tumorigenesis using the polyoma middle T antigen
245 ects of MAT expression on the development of mammary tumorigenesis using transgenic mice that express
246 we showed that LILRB4 regulates CRD-induced mammary tumorigenesis via a non-canonical WNT signaling
247 Oncogenes Neu/HER2/ErbB2 and Ras can induce mammary tumorigenesis via upregulation of cyclin D1.
251 importance of cyclin D1 in ERalpha-mediated mammary tumorigenesis, we crossed ERalpha-overexpressing
252 ed to be a key mediator for ErbB2-associated mammary tumorigenesis, we deleted Jak2 from ErbB2-expres
255 r signal-regulated kinases (ERK) 1/2 promote mammary tumorigenesis, we examined the real-time behavio
256 equirement for Cdk2 in LMW-cyclin E-mediated mammary tumorigenesis, we generated transgenic mice, whi
257 To examine whether AIB3 reduction affects mammary tumorigenesis, we generated wild-type mouse mamm
258 le of CSF-1 or its receptor in initiation of mammary tumorigenesis, we have generated two independent
259 ne whether CK2 overexpression contributes to mammary tumorigenesis, we have performed comparative stu
260 hat may be causally involved in MMTV-induced mammary tumorigenesis, we identified 60 sites of provira
261 TNFRSF11A (also known as RANK) contribute to mammary tumorigenesis, we investigated a role for this p
263 transgenic mouse models for HER2/neu-induced mammary tumorigenesis, we report that Hunk is required f
264 entify genes that cooperate with TGFalpha in mammary tumorigenesis, we used a retroviral insertion ap
265 insic susceptibilities to carcinogen-induced mammary tumorigenesis were each shown to display signifi
266 n this study, the effects of black cohosh on mammary tumorigenesis were investigated in the MMTV-neu
267 ) and reduced N-methyl-N-nitrosourea-induced mammary tumorigenesis when administered to female Spragu
268 man breast cancer and is capable of inducing mammary tumorigenesis when overexpressed in transgenic m
270 knockout of FIP200 significantly suppressed mammary tumorigenesis, which was accompanied by accumula
271 f activated Her2/Neu resulted in accelerated mammary tumorigenesis with enhanced metastatic potential
272 tumor incidence and triggered early onset of mammary tumorigenesis with increased lung metastasis in
273 ygous status significantly accelerated mouse mammary tumorigenesis with reduced apoptosis and increas
274 three-dimensional matrices, a mouse model of mammary tumorigenesis with vinculin mutants, and a novel
275 els and an autochthonous transgenic model of mammary tumorigenesis, with less overall tumour cell dea
276 to a tumor promoter occurs frequently during mammary tumorigenesis, yet the molecular mechanisms unde